These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 32770851)

  • 1. Real-world long-term effectiveness of ustekinumab in Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Iglesias-Flores E; Navarro P; Rivero M; Gutiérrez A; Sierra-Ausin M; Mesonero F; Ferreiro-Iglesias R; Hinojosa J; Calvet X; Sicilia B; González-Muñoza C; Antolín B; González-Vivo M; Carbajo AY; García-López S; Martín-Cardona A; Surís G; Martin-Arranz MD; de Francisco R; Cañete F; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2020 Sep; 52(6):1017-1030. PubMed ID: 32770851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry.
    Iborra M; Beltrán B; Fernández-Clotet A; Gutiérrez A; Antolín B; Huguet JM; De Francisco R; Merino O; Carpio D; García-López S; Mesonero F; Navarro P; Ferreiro-Iglesias R; Carbajo AY; Rivero M; Gisbert JP; Piñero-Pérez MC; Monfort D; Bujanda L; García-Sepulcre MF; Martín-Cardona A; Cañete F; Taxonera C; Domènech E; Nos P;
    Aliment Pharmacol Ther; 2019 Aug; 50(3):278-288. PubMed ID: 31222872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates.
    Verstockt B; Dreesen E; Noman M; Outtier A; Van den Berghe N; Aerden I; Compernolle G; Van Assche G; Gils A; Vermeire S; Ferrante M
    J Crohns Colitis; 2019 Jul; 13(7):864-872. PubMed ID: 30715258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
    García MJ; Rivero M; Fernández-Clotet A; de Francisco R; Sicilia B; Mesonero F; de Castro ML; Casanova MJ; Bertoletti F; García-Alonso FJ; López-García A; Vicente R; Calvet X; Barreiro-de Acosta M; Ferrer Rosique J; Varela Trastoy P; Nuñez A; Ricart E; Riestra S; Arias García L; Rodríguez M; Arranz L; Pajares R; Mena R; Calafat M; Camo P; Bermejo F; Ponferrada Á; Madrigal RE; Llaó J; Sesé E; Sánchez E; Pineda Mariño JR; González Muñoza C; Carbajo López AY; Julián AB; Villoria Ferrer A; Baston-Rey I; Jara L; Almela P; Codesido L; de la Maza S; Leal C; Caballol B; Pérez-Martínez I; Vinuesa Campo R; Crespo J; Domènech E; Chaparro M; Gisbert JP
    J Crohns Colitis; 2024 Jan; 18(1):65-74. PubMed ID: 37522878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease.
    Ollech JE; Normatov I; Peleg N; Wang J; Patel SA; Rai V; Yi Y; Singer J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT; Pekow J
    Clin Gastroenterol Hepatol; 2021 Jan; 19(1):104-110. PubMed ID: 32109634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry.
    Casas-Deza D; Lamuela-Calvo LJ; Gomollón F; Arbonés-Mainar JM; Caballol B; Gisbert JP; Rivero M; Sánchez-Rodríguez E; Arias García L; Gutiérrez Casbas A; Merino O; Márquez L; Laredo V; Martín-Arranz MD; López Serrano P; Riestra Menéndez S; González-Muñoza C; de Castro Parga L; Calvo Moya M; Fuentes-Valenzuela E; Esteve M; Iborra M; Dura Gil M; Barreiro-De Acosta M; Lorente-Poyatos RH; Manceñido N; Calafat M; Rodríguez-Lago I; Guardiola Capo J; Payeras MA; Morales Alvarado VJ; Tardillo C; Bujanda L; Muñoz-Nuñez JF; Ber Nieto Y; Bermejo F; Almela P; Navarro-Llavat M; Martínez Montiel P; Rodríguez Gutiérrez C; Van Domselaar M; Sesé E; Martínez Pérez T; Ricart E; Chaparro M; García MJ; López-Sanromán A; Sicilia B; Orts B; López-García A; Martín-Arranz E; Pérez-Calle JL; de Francisco R; García-Planella E; Domènech E; García-López YS
    J Crohns Colitis; 2023 Jan; 17(1):83-91. PubMed ID: 35913456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
    af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
    Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study.
    Biemans VBC; van der Meulen-de Jong AE; van der Woude CJ; Löwenberg M; Dijkstra G; Oldenburg B; de Boer NKH; van der Marel S; Bodelier AGL; Jansen JM; Haans JJL; Theeuwen R; de Jong D; Pierik MJ; Hoentjen F
    J Crohns Colitis; 2020 Jan; 14(1):33-45. PubMed ID: 31219157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease.
    Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Halfvarson J; Ludvigsson JF
    Dig Dis Sci; 2023 Jan; 68(1):65-76. PubMed ID: 35459973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between Ustekinumab trough concentrations and clinical, biochemical and endoscopic outcomes in Crohn's disease: A multi-center nationwide retrospective study (TARGET STUDY).
    Shehab M; Abdullah I; Alfadhli A; Alrashed F
    Medicine (Baltimore); 2024 Jul; 103(27):e38804. PubMed ID: 38968490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
    Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
    Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(9):1232-1243. PubMed ID: 28252210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
    Liefferinckx C; Verstockt B; Gils A; Noman M; Van Kemseke C; Macken E; De Vos M; Van Moerkercke W; Rahier JF; Bossuyt P; Dutré J; Humblet E; Staessen D; Peeters H; Van Hootegem P; Louis E; Franchimont D; Baert F; Vermeire S;
    J Crohns Colitis; 2019 Oct; 13(11):1401-1409. PubMed ID: 30989232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short term effectiveness of ustekinumab versus vedolizumab in Crohn's disease after failure of anti-TNF agents: An observational comparative study design with a Bayesian analysis.
    Alamer A; Al Lehaibi LH; Alomar M; Aldhuwayan F; Alshouish S; Al-Ali AY; Almudhry Z; Almulhim A; Althagafi A; Aldosari S; AlAmeel T
    Saudi J Gastroenterol; 2024 Sep; 30(5):324-334. PubMed ID: 39157885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.
    Ma C; Fedorak RN; Kaplan GG; Dieleman LA; Devlin SM; Stern N; Kroeker KI; Seow CH; Leung Y; Novak KL; Halloran BP; Huang VW; Wong K; Blustein PK; Ghosh S; Panaccione R
    Inflamm Bowel Dis; 2017 May; 23(5):833-839. PubMed ID: 28328624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Ustekinumab Optimization by 2 Initial Intravenous Doses in Adult Patients With Severe Crohn's Disease.
    Ren H; Kang J; Wang J; Su J; Zou L; Yin A; Li J; Zhou Q; Wang W; Tang Z; Zhang J; Lu Y; Yang Y; Qiu C; Ding Y; Dong W; An P
    Inflamm Bowel Dis; 2024 Aug; 30(8):1295-1302. PubMed ID: 37619248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up.
    Forss A; Clements M; Myrelid P; Strid H; Söderman C; Wagner A; Andersson D; Hjelm F; ; Olén O; Ludvigsson JF; Halfvarson J
    Scand J Gastroenterol; 2021 Jun; 56(6):680-686. PubMed ID: 33794731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease.
    Battat R; Kopylov U; Bessissow T; Bitton A; Cohen A; Jain A; Martel M; Seidman E; Afif W
    Clin Gastroenterol Hepatol; 2017 Sep; 15(9):1427-1434.e2. PubMed ID: 28365485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ustekinumab concentrations shortly after escalation to monthly dosing may identify endoscopic remission in refractory Crohn's disease.
    Hanžel J; Koželj M; Špes Hlastec A; Kurent T; Sever N; Zdovc J; Smrekar N; Novak G; Štabuc B; Grabnar I; Drobne D
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e831-e836. PubMed ID: 34402470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of methotrexate monotherapy in patients with Crohn's disease refractory to anti-TNF-α: results from the ENEIDA registry.
    Mesonero F; Castro-Poceiro J; Benítez JM; Camps B; Iborra M; López-García A; Torres P; Esteve M; Tosca J; Bertoletti F; Almela P; Calvet X; Vera I; Bujanda L; Gomollón F; Rodríguez C; Antolín B; Busquets D; Hernández A; Rivero M; Monfort I Miquel D; Castaño-García A; Gisbert JP; Domènech E; López-Sanromán A;
    Aliment Pharmacol Ther; 2021 May; 53(9):1021-1029. PubMed ID: 33715177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.